The US Food and Drug Administration (FDA) has granted Neuros Medical investigational device exemption approval to initiate a pilot clinical trial to investigate its patented high-frequency electrical nerve-block technology, designed for the acute treatment of pain in the residual limbs of amputees.

The technology will eliminate chronic pain in a number of applications, such as amputation pain, chronic post-surgical pain, chronic migraine and trigeminal neuralgia.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The approval is supported by the first-in-man feasibility study, in which four out of five patients reported improvements in pain, reducing pain scores to zero.

Neuros Medical president and CEO Jon Snyder said the company will further commence the pilot study to provide long term safety and efficacy data of electrical nerve block technology in a larger set of patients.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact